Tag Archives: MCRI

2019, Stem Cells Australia, Tomorrow's Medicine Starts Today

Fixing hearts by finding out what makes them tick

You can learn a lot about hearts by trying to build one from scratch. A pair of scientists have grown ‘beating’ human heart muscle tissue from stem cells and are exploring cardiac regeneration.

Developmental biologist Associate Professor Enzo Porrello became interested in how newborn mammal hearts can regenerate while working in Dallas, Texas at one of the leading labs researching heart development.

Associate Professor James Hudson has a background in chemical and biological engineering. In Germany, he developed bioengineering techniques to make force-generating human heart tissue at the University Medical Center in Göttingen. Continue reading Fixing hearts by finding out what makes them tick →

2019, Stem Cells Australia, Tomorrow's Medicine Starts Today

Mini-kidneys tell two sides of a genetic story

Gene editing technology combined with stem cells provides a powerful new way to study genetic kidney diseases and their treatments.

Melbourne researchers have used mini-kidney ‘organoids’ grown in the lab to unravel the mystery of why Mainzer-Saldino syndrome, a rare disease involving a single defective gene, causes life-threatening kidney damage. In doing so, they’ve proven an approach that can be used to study a whole range of other genetic kidney diseases. Continue reading Mini-kidneys tell two sides of a genetic story →

2016, Australia-Indonesia Collaboration

Keeping ahead of a child killer: stopping gastro from birth

UPDATE 22 February 2018:  

A vaccine has been developed against rotavirus, which is the common cause  of severe diarrhoea and a killer of approximately 215,000 children under five globally each year.

The oral vaccine was given in three single doses, the first within five days of birth. After three doses of RV3-BB administered from birth:

  • 94 per cent of infants were protected in their first year of life against severe rotavirus gastroenteritis
  • 75 per cent of infants were protected to 18 months of age.

The success of the RV3-BB vaccine is the culmination of more than four decades of work, which started with the Murdoch Children’s Research Institute’s Professor Ruth Bishop and the discovery of rotavirus in 1973.

The trial was funded by the National Health and Medical Research Council (NHMRC), Bill & Melinda Gates Foundation and PT BioFarma.

Read the full media release on the MCRI website.

——

A new rotavirus vaccine should soon be available thanks to a collaboration between PT Bio Farma and researchers in Melbourne and Yogyakarta. The new ‘RV3’ vaccine is aimed at protecting babies from birth, improving protection and simplifying delivery.

The current vaccine, available in Australia and only on the private market in Indonesia, can only be administered from six weeks of age.

Continue reading Keeping ahead of a child killer: stopping gastro from birth →